Abstract
A Prospective Multicenter Study of Minimal Residual Disease Assessment Using a Next-Generation Immunosequencing Assay and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have